Review Article
Immunohistochemical Biomarkers in Gastric Cancer Research and Management
Table 1
Immunohistochemical markers in GC.
| IHC marker | Parameter | Reference |
| HER2 | Prognosis | [19–23] | Therapeutic response | [24] | Lymph node metastasis | [25] | Lauren histotype | [26, 27] |
| VEGF | Prognosis | [28–31] | Lauren histotype | [32] | Tumor progression | [33] | Therapeutic response | [34] |
| hERG1 | Prognosis | [35] |
| KLF5 | Grading | [36] | Stage | [36, 37] | Lymph node status | [36, 37] | Prognosis | [36, 37] |
| CA IX | Lymph node metastasis | [38] | Prognosis | [38] |
| Ki67 | Lymph node metastasis | [25] |
| PKP3 | Stage | [39] | Prognosis | [39] |
| MMP-2 | Prognosis | [29, 31] | HDAC | Prognosis | [40–42] | Bcl-2 | Lymph node metastasis | [25] | Bcl-6 | Prognosis | [43] |
| SATB1 | Lymph node metastasis | [44, 45] | Distant metastasis | [44, 45] | Stage | [44, 45] |
| c-myc2 | Lymph node metastasis | [25] | TGF β | Stage | [46] |
| E-cadherin | Prognosis | [31, 47–52] | Invasion | [53] | Grading | [54, 55] | Lauren histotype | [54] |
| COX-2 | Prognosis | [56] | TSP-1 | Prognosis | [57] | Bax | Prognosis | [58, 59] |
|
|